Clinical trials: sponsored by Dana-Farber Cancer Institute
Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.
- Conditions
- Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney, Epithelioid Sarcoma, Chordoma (Poorly Differentiated or De-differentiated)
- Trial name
- NCT04416568
- Testing
- Nivolumab, Ipilimumab
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Non Small Cell Lung Cancer, Small Cell Lung Carcinoma
Biology of Young Lung Cancer Study: The YOUNG LUNG Study
The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.
- Conditions
- Non Small Cell Lung Cancer, Small Cell Lung Carcinoma, NUT Carcinoma
- Trial name
- NCT05265429
- Testing
- Data and Specimen Collection
- Where
- 4 sites in United States
- Volunteers
- 500 people
- Sponsor
- Dana-Farber Cancer Institute
Cancer, Quality of Life
The PRISM Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced Cancer
Multi-Site Randomized Controlled Trial testing the efficacy of the Promoting Resilience in Stress Management (PRISM) intervention among Adolescents and Young Adults with Advanced Cancer
- Conditions
- Cancer, Quality of Life, Anxiety, Depression
- Trial name
- PRISM-AC (NCT03668223)
- Testing
- Promoting Resilience in Stress Management (PRISM)
- Where
- 5 sites in United States
- Volunteers
- 269 people
- Sponsor
- Dana-Farber Cancer Institute
Pediatric Cancer, Financial Stress
PediRISE Feasibility
The goal of this research study is to learn whether investigators can successfully give the PediRISE program to families-in other words, whether most families are interested in participating in a study about the PediRISE program…
- Conditions
- Pediatric Cancer, Financial Stress, Financial Hardship, Disparities
- Trial name
- NCT06283251
- Testing
- PediRISE Resource Program
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Dana-Farber Cancer Institute
Osteosarcoma, Osteosarcoma Recurrent
Olaparib With Ceralasertib in Recurrent Osteosarcoma
This study is being done in order to evaluate the effectiveness of using two drugs (olaparib and ceralasertib) to treat patients with osteosarcoma that has not responded to treatment or has come back after treatment The names of…
- Trial name
- NCT04417062
- Testing
- Olaparib, Ceralasertib
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- Dana-Farber Cancer Institute
Pediatric Solid Tumor
The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study
This research study is evaluating the use of specialized testing of solid tumors including sequencing. The process of performing these specialized tests is called tumor profiling.
- Trial name
- NCT02520713
- Testing
- Genetic testing and GAIN report
- Where
- 12 sites in United States
- Volunteers
- 825 people
- Sponsor
- Dana-Farber Cancer Institute
Childhood Cancer, Childhood Cancer Survivors
Proof-of-Concept Testing of the Cardiovascular Health Equity Through Food (CHEF) Intervention in Childhood Cancer Survivors
The goal of the Cardiovascular Health Equity Through Food (CHEF) program is to make it easier for participants and families to cook and eat healthy foods during and following childhood cancer treatment with the long-term goal of…
- Trial name
- CHEF (NCT06609473)
- Testing
- CHEF Intervention Program
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Dana-Farber Cancer Institute
CNS Tumor, Solid Tumor
Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS Tumors
This study is looking to learn whether a tumor testing approach can feasibly measure antibody-drug conjugate (ADC) target proteins in children and young adults with relapsed or refractory solid tumors or central nervous system…
- Conditions
- CNS Tumor, Solid Tumor, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT07793994
- Testing
- Bulk RNA Sequencing, Immunohistochemistry (IHC)
- Where
- 2 sites in United States
- Volunteers
- 130 people
- Sponsor
- Dana-Farber Cancer Institute
Sarcoma, Bone Sarcoma
Bridging Adolescent and Young Adult Sarcoma Survivors With Personalized Oncology Exercise Service (AYA-ONE): A Pilot Intervention
This study will evaluate strategies to improve physical function and promote exercise and physical activity in adolescents and young adults (AYAs) with sarcoma.
- Conditions
- Sarcoma, Bone Sarcoma, Soft Tissue Sarcoma (STS)
- Trial name
- AYA-ONE (NCT07662239)
- Testing
- Exercise Triage and Personalized Exercise Program
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Lymphoblastic Leukemia ALL
Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL
This research study is evaluating a drug called ribociclib (LEE011) given in combination with everolimus and other standard of care chemotherapy drugs as a possible treatment for relapsed or refractory ALL.
- Trial name
- NCT03740334
- Testing
- Ribociclib, Dexamethasone, Everolimus
- Where
- 12 sites in United States
- Volunteers
- 45 people
- Sponsor
- Dana-Farber Cancer Institute
Cancer Risk, Cancer Predisposition Syndrome
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member…
- Conditions
- Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors
- Trial name
- NCT05463796
- Testing
- Samples
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Recurrent, Refractory, or High Risk Leukemias, Matched Targeted Therapy
Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome
This research study is seeking to gain new knowledge about Recurrent, Refractory, or High Risk Leukemias in children and young adults. This study is evaluating the use of specialized testing called leukemia profiling.
- Trial name
- NCT02670525
- Testing
- Leukemia Profiling
- Where
- 15 sites in United States
- Volunteers
- 338 people
- Sponsor
- Dana-Farber Cancer Institute
Drug/Agent Toxicity by Tissue/Organ, Leukemia
05-001: Treatment of Acute Lymphoblastic Leukemia in Children
RATIONALE: L-asparaginase is an important component of treatment for childhood acute lymphoblastic leukemia, but is also associated with notable side-effects, including hypersensitivity, pancreatitis, and thrombosis.
- Trial name
- NCT00400946
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- 8 sites in United States, Canada
- Volunteers
- 800 people
- Sponsor
- Dana-Farber Cancer Institute
Cancer Risk Syndrome
Intervention For Adolescents and Young Adults (AYAs) With Cancer Risk Syndromes
This research is being done because there is a need to improve cancer risk communication and decision-making among adolescents and young adults.
- Trial name
- AYA-RISE (NCT04323774)
- Testing
- AYA-RISE Adolescents and Young Adults Risk Information and Screening Education, Standard clinical visit for genetic counseling
- Where
- 5 sites in United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma
This study is being conducted to learn about the effects of SC-PEG, which is a new form of a chemotherapy drug called asparaginase. Asparaginase is used to treat ALL and lymphoblastic lymphoma.
- Trial name
- NCT01574274
- Testing
- SC-PEG, Oncaspar
- Where
- 8 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Dana-Farber Cancer Institute
Stem Cell Transplant Complications, Sleep Disturbance
Developing Restful Environments and Management Strategies for Pediatric Stem Cell Transplant Patients
Pediatric patients undergoing stem cell transplant (SCT) are hospitalized for extended periods and are at high risk for sleep disturbances.
- Trial name
- DREAMS (NCT06468618)
- Testing
- DREAMS Program Video and Care Kit
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Lymphoblastic Leukemia, Pediatric
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The cancer comes from a cell in the blood called a lymphocyte.
- Trial name
- NCT03020030
- Testing
- Pegaspargase, Erwinia asparaginase, Cyclophosphamide
- Where
- 9 sites in United States, Canada
- Volunteers
- 560 people
- Sponsor
- Dana-Farber Cancer Institute
Leukemia, Myelodysplastic Syndromes
Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens
This research study is a genomic profiling and repository study for children and young adults who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS).
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myeloproliferative Syndrome
- Trial name
- NCT04968834
- Testing
- Genomic profiling
- Where
- 8 sites in United States
- Volunteers
- 300 people
- Sponsor
- Dana-Farber Cancer Institute
Langerhans Cell Histiocytosis
Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
This research study is evaluating a drug called clofarabine as a possible treatment for Langerhans Cell Histiocytosis (LCH) and and other histiocytic disorders.
- Trial name
- NCT02425904
- Testing
- Clofarabine
- Where
- 15 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
This research study is studying cytokine induced memory-like natural killer (CIML NK) cells combined with IL-2 in adult patients (18 years of age or older) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Juvenile Myelomonocytic Leukemia
- Trial name
- NCT04024761
- Testing
- CIML NK, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Dana-Farber Cancer Institute